Helping addiction clinics offer clean needles and HIV prevention pills
Tests clinic support for HIV prevention among people who inject drugs.
Plain-language title generated from the registry record
Registry title: Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
Key facts
- Where
- Pittsburgh, United StatesSee the 4 sites
Where in United States
- Center for Psychiatric And Chemical Dependency ServicesPittsburgh, United StatesNo longer taking part
- Internal Medicine Recovery Engagement ProgramPittsburgh, United StatesNo longer taking part
- Latterman Family Health CenterPittsburgh, United StatesNo longer taking part
- UPMC-Magee Womens HospitalPittsburgh, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT07073924
- Record updated
- 6 November 2026
- Original description
In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID. This study is supported by the HEAL Initiative (https://heal.nih.gov/).Read full original descriptionShow less
Prescribe to Prevent HIV (P2PH): Enhancing Clinic-based Prescribing of Harm Reduction: A Clinical Trial to Prevent HIV and Severe Injection-related Infections Among PWID
In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID. This study is supported by the HEAL Initiative (https://heal.nih.gov/).
Inclusion: -Adult patients with history of active injection drug use in the past 1 year from the 4 COEs; -Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs.
Exclusion: Residence or discharge to a treatment facility that bans the possession of drug checking supplies; If history of injection drug use >1 year; Acute, severe psychiatric condition in need of immediate treatment; Clinical Partners:; Pre-implementation interviews (N=12), pre-implementation focus groups (N = 24), post-implementation surveys (N = 80), and post-implementation interviews (N=10); Ages <18; Non-English speaking; Pending or legal action that could prohibit or interfere with participation (Ie. incarceration); Individuals not affiliated with the 4 COEs; Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses); Students, trainees, or individuals not credentialed in the eligible roles; Those on extended leave or not actively working during the study period.
Patients:; Pre-implementation interviews (N=12), pre-implementation focus groups (N=8), and post-implementation interviews (N=10).